NASDAQ: OCX
Oncocyte Corp Stock Ownership - Who owns Oncocyte?

Insider buying vs selling

Have Oncocyte Corp insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Broadwood Partners LP10% Owner2024-10-021,315,339$2.95
$3.88MBuy
Andrea S. JamesChief Financial Officer2024-10-0233,670$2.97
$100.00kBuy
Andrew ArnoDirector2024-04-1133,898$2.95
$100.00kBuy
Broadwood Partners LP10% Owner2024-04-112,420,000$2.92
$7.06MBuy
Josh RiggsCEO and President2024-04-113,390$2.95
$10.00kBuy

1 of 1

OCX insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when OCX insiders and whales buy or sell their stock.

OCX Shareholders

What type of owners hold Oncocyte Corp stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Pura Vida Investments LLC207.44%34,922,779$85.21MInsider
Broadwood Partners LP124.51%20,960,766$51.14MInsider
Lineage Cell Therapeutics Inc35.88%6,041,154$14.74MInsider
Broadwood Capital Inc29.28%4,929,066$12.03MInstitution
John Peter Gutfreund29.11%4,900,047$11.96MInsider
George Karfunkel21.74%3,659,860$8.93MInsider
Awm Investment Company Inc6.52%1,097,175$2.68MInstitution
Alfred D. Kingsley3.58%601,990$1.47MInsider
Ronald Asbury Andrews3.46%583,212$1.42MInsider
Pura Vida Investments LLC2.94%495,345$1.21MInstitution

1 of 3

OCX vs Diagnostic & Research Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
OCX8.90%91.10%Net BuyingNet Buying
PMAX0.34%0.00%
STIM34.87%53.57%Net BuyingNet Buying
PRE9.10%0.00%
DRIO23.53%46.85%Net BuyingNet Buying

Oncocyte Stock Ownership FAQ

Who owns Oncocyte?

Oncocyte (NASDAQ: OCX) is owned by 42.57% institutional shareholders, 435.67% Oncocyte insiders, and 0.00% retail investors. Pura Vida Investments LLC is the largest individual Oncocyte shareholder, owning 34.92M shares representing 207.44% of the company. Pura Vida Investments LLC's Oncocyte shares are currently valued at $85.21M.

If you're new to stock investing, here's how to buy Oncocyte stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.